Contact this trialFirst, we need to learn more about you.
Radiopharmaceutical
[68Ga]Pentixafor for Neuroendocrine Cancer
Recruiting1 awardPhase < 1
Iowa City, Iowa
This trial uses Gallium-68 Pentixafor, an imaging agent for PET scans, to detect high-grade neuroendocrine tumors. It targets specific markers on these tumors and makes them visible on scans. The study aims to see how consistently this agent works across different scans.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service